NCT07361510 | CA266-0002 | DRUG CO

Clinical Trial: NCT07361510 | CA266-0002 | DRUG CO

NCT Number: NCT07361510

Protocol ID: CA266-0002

Sponsor: DRUG CO

Disease Site: Lung- Non-Small Cell Lung Cancer

Disease Category: Lung

Detail: ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 â‰¥ 50%

For more details, click here.

Interested in participating in this trial?

Clinical Trial

First Name

Last Name

Phone

Preferred Contact Method:

Preferred Location:

Patient Type:

Current Patient New Patient

Interested in:

Cancer Clinical Trial Blood Disorder Clinical Trial

Disease Site:

Disease Category

What do all the numbers mean on clinical trials?

National Clinical Trial Identifier

The National Clinical Trial (NTC) is assigned by the National Library of Medicine when a new study appears in the clinical trials database.

ex: NCT0526225 | GY026 | NRG

PROTOCOL IDENTIFICATION NUMBER

Any unique identifier assigned to the protocol by the sponsor.

ex: NCT0526225 | GY026 | NRG

STUDY SPONSOR

A sponsor is an individual, institution, company or organization that takes the responsibility to initiate, manage and/or finance the clinical trial.

ex: NCT0526225 | GY026 | NRG